30 days ago - “We are preparing our IND submission for Phase I and II human clinical trials to evaluate safety and immunogenicity of the Ii-Key vaccine, and plan to submit the IND to the FDA as soon as the GMP production of the Ii-Key vaccine is completed in the coming weeks."

We should be just about there for the following items:
IND submission
Expected 8K
China / Malaysia update
Nasdaq NGIO